Salomon & Ludwin’s GSK GSK Stock Holding History

Salomon & Ludwin’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.3K	Sell	1,195 -502	-30%	-$26.5K	0.01%	455
2026 Q1	$96.2K	Buy	1,697 +664	+64%	+$36K	0.01%	261
2025 Q4	$50.6K	Buy	1,033 +81	+9%	+$3.78K	﹤0.01%	408
2025 Q3	$41.3K	Buy	952 +777	+444%	+$30.4K	﹤0.01%	435
2025 Q2	$6.74K	Buy	175 +25	+17%	+$955	﹤0.01%	529
2025 Q1	$5.81K	Hold	150	–	–	﹤0.01%	504
2024 Q4	$5.07K	Sell	150 -8	-5%	-$288	﹤0.01%	512
2024 Q3	$6.46K	Hold	158	–	–	﹤0.01%	507
2024 Q2	$6.08K	Hold	158	–	–	﹤0.01%	508
2024 Q1	$6.77K	Sell	158 -22	-12%	-$907	﹤0.01%	597
2023 Q4	$6.53K	Hold	180	–	–	﹤0.01%	547
2023 Q3	$6.53K	Buy	+180	New	+$6.39K	﹤0.01%	545

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Salomon & Ludwin's GSK Position: Q2 2026 in Review

Salomon & Ludwin reduced its GSK (GSK) stake by 30% in Q2 2026, selling an estimated $26.5K and leaving 1,195 shares worth $61.3K. The position accounts for 0.01% of the portfolio, ranked #455.

Salomon & Ludwin first reported a position in GSK in Q3 2023 and has held it in 12 quarters since. The position peaked at $96.2K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Salomon & Ludwin held 1,195 shares of GSK worth $61.3K as of Q2 2026.
Salomon & Ludwin sold 502 GSK shares in Q2 2026, an estimated $26.5K.
GSK made up 0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #455 holding.
Salomon & Ludwin first reported a position in GSK in Q3 2023 and has held it in 12 quarters since.
Salomon & Ludwin's GSK position peaked at $96.2K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.